Anthem BioSciences

Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Pvt. Ltd.)
49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra. Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: July 21, 2026

To,

BSE Limited,	National Stock Exchange of India Limited
20th Floor, P.J. Towers,	Exchange Plaza, C-1, Block G,
Dalal Street,	Bandra Kurla Complex, Bandra (E),
Mumbai - 400001.	Mumbai – 400 051
BSE Scrip Code: 544449	NSE Scrip Symbol: ANTHEM

Subject: Outcome of the Board Meeting held on Tuesday, July 21, 2026

Dear Sir/Ma'am

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that the Board of Directors of Anthem Biosciences Limited *(formerly known as Anthem Biosciences Private Limited)* ("Company") at their meeting held on Tuesday, July 21, 2026 which commenced at 01:45 p.m. and concluded at 03:35 p.m. have inter-alia, approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of Statutory Auditors for the quarter ended June 30, 2026. The said financials results were duly reviewed and recommended by Audit Committee at its meeting held on same day to the Board.

A copy of the said Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Statutory Auditors are enclosed herewith and the extract of the results will be published in the newspapers as required under Regulation 47(1) of SEBI LODR Regulations.

The above intimation is also available on the Company's website at https://anthembio.com/.

We request you to kindly take the same on record.

Thanking you,
Yours truly,
For Anthem Biosciences Limited
(*Formerly known as Anthem Biosciences Private Limited*)

DIVYA PRASAD
Digitally signed by DIVYA PRASAD
Date: 2026.07.21 16:19:07 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

K. P. RAO & CO.
CHARTERED ACCOUNTANTS

'Poornima', IInd Floor, 25, State Bank Road,
Bangalore - 560 001. Karnataka, India.

K. P. RAO
H.N. ANIL
MOHAN R LAVI

K. VISWANATH
S. PRASHANTH
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814
Fax : 080 - 25594661
E-mail : info@kprao.co.in

Independent Auditor's Review Report on the quarterly Unaudited Standalone Financial results of Anthem Biosciences Limited pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review report to
The Board of Directors of
Anthem Biosciences Limited
Bangalore

1. We have reviewed the Unaudited Standalone Financial result of Anthem Biosciences Limited (the "Company"), for the quarter ended June 30, 2026 included in the accompanying "Statement of Unaudited Standalone Financial results for the quarter ended June 30, 2026" (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).

2. This statement, which is the responsibility of the Company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

K.P. RAO & CO. BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K. P. Rao & Co.,
Chartered Accountants
FRN: 003135S

K.P. RAO & CO. ★ BENGALURU FRN:003135S CHARTERED ACCOUNTANTS ★

Mohan R Lavi
Partner
Membership No. 029340

Place: Bangalore
Date: July 21, 2026

UDIN: 26029340ETJRWW4382

ANTHEM BIOSCIENCES LIMITED
CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703
REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA.
Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Particulars	Quarter ended			Rs in Mn Year End
	30/06/2026	31/03/2026	30/06/2025	31/03/2026
	Unaudited	Unaudited	Unaudited	Audited
Income:				
Revenue from operations	3,838.42	5,825.01	5,380.11	20,893.12
Other income	286.00	606.25	277.28	1,820.75
Total Income	**4,124.42**	**6,431.26**	**5,657.39**	**22,713.87**
Expenses:				
Cost of materials consumed	1,449.45	1,500.74	1,623.95	6,967.51
Changes in inventories of finished goods, work-in-progress and stock in trade	(23.64)	502.54	686.72	986.91
Employee benefit expenses	727.79	667.25	685.69	2,639.24
Finance cost	7.63	15.83	16.06	65.47
Depreciation and amortisation expense	223.10	262.84	226.12	995.65
Other expenses	376.49	484.57	429.46	1,788.25
Total Expenses	**2,760.82**	**3,433.76**	**3,668.01**	**13,443.04**
Profit before exceptional items and tax	**1,363.60**	**2,997.50**	**1,989.38**	**9,270.84**
Exceptional items	-	(9.71)	-	240.13
Profit before tax	**1,363.60**	**3,007.21**	**1,989.38**	**9,030.70**
Tax expense				
Current tax	347.05	897.06	500.69	2,413.05
Deferred tax	(3.55)	(6.50)	5.29	(87.99)
Total tax expenses	**343.50**	**890.56**	**505.98**	**2,325.06**
Profit for the Period/Year	**1,020.09**	**2,116.65**	**1,483.40**	**6,705.64**
Other comprehensive income				
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	9.37	(10.93)	20.08	(20.04)
Income tax on above	(2.36)	2.75	(5.05)	5.04
Other comprehensive income/(loss) to be reclassified to profit or loss in subsequent period	2.83	-	-	-
Income tax on above	(0.71)	-	-	-
Other comprehensive income/(loss) for the period/year	**9.13**	**(8.18)**	**15.03**	**(15.00)**
Total comprehensive income for the period/year	**1,029.22**	**2,108.47**	**1,498.43**	**6,690.64**
Paid-up equity share capital (face value of Rs.2 each)	**1,126.77**	**1,123.43**	**1,123.22**	**1,123.43**
Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				**30,723.58**
Earnings per share	*Not annualised*	*Not annualised*	*Not annualised*	*Annualised*
Basic	1.81	3.77	2.65	11.95
Diluted	1.80	3.73	2.64	11.82

See accompaning notes to financial results

K.P. RAO & CO. BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

Anthem Biosciences Limited Bangalore

Notes to standalone financial results

1 These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") .

2 The above statement of unaudited standalone financial results ("the Statements") of the Company for the quarter ended 30th June 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on July 21, 2026. The Statutory Auditor have expressed an unmodified opinion.

3 During the quarter, the company has allotted 1,670,909 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on May 19, 2026 & June 16, 2026.

4 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

For and on behalf of the board of directors of
Anthem Biosciences Limited
CIN:L24233KA2006PLC039703

Ajay Bhardwaj
Managing Director
DIN: 00333704

Place: Bangalore
Date: July 21, 2026

K. P. RAO & CO.
CHARTERED ACCOUNTANTS

'Poornima', IInd Floor, 25, State Bank Road,
Bangalore - 560 001. Karnataka, India.

K. P. RAO
H.N. ANIL
MOHAN R LAVI
K. VISWANATH
S. PRASHANTH
P. RAVINDRANATH

Phone : 080 - 25587385 / 25586814
Fax : 080 - 25594661
E-mail : info@kprao.co.in

Independent Auditor's Review Report on the quarterly Unaudited Consolidated Financial Results of Anthem Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review report to
The Board of Directors of
Anthem Biosciences Limited
Bangalore

1. We have reviewed the Unaudited Consolidated Financial Results of Anthem Biosciences Limited (the " Holding Company") and its one subsidiary (the Company and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2026 included in the accompanying "Statement of Unaudited Consolidated Financial results for the quarter ended June 30, 2026", (the Statement) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (Listing Regulations).

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, as amended. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of the Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, as amended to the extent applicable.

K.P. RAO & CO. ★ BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

The Statement includes the results of Neoanthem Lifesciences Private Limited (a wholly owned subsidiary).

4. The Statement includes the unaudited financial results of one subsidiary, whose financial statements reflect total revenue (before consolidation adjustments) of Rs. 358.05 million and total net profit (before consolidation adjustments) of Rs. 82.22 million and total comprehensive Income (net) of Rs. 179.39 million for the quarter ended on that date, as considered in the Statement, which have been reviewed by us.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K. P. Rao & Co.,
Chartered Accountants
FRN: 003135S

K.P. RAO & CO. BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

Mohan R Lavi
Partner
Membership No. 029340

Place: Bangalore
Date: July 21, 2026

UDIN: 26029340COIEOX8551

ANTHEM BIOSCIENCES LIMITED
CORPORATE IDENTITY NUMBER: L24233KA2006PLC039703

REGISTERED AND CORPORATE OFFICE: NO 49, F1&F2, CANARA BANK ROAD, BOMMASANDRA INDUSTRIAL AREA, PHASE-I, BOMMASANDRA, BANGALORE-560099. KARNATAKA INDIA.

Email : investors.abl@anthembio.com Telephone: +91 080 6672 4000 Website: www.anthembio.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Rs in Mn

Particulars	Quarter ended			Year End
	30/06/2026	31/03/2026	30/06/2025	31/03/2026
	Unaudited	Unaudited	Unaudited	Audited
Income:				
Revenue from operations	4,182.18	6,109.43	5,402.09	21,243.33
Other income	248.88	512.12	228.12	1,557.83
Total income	**4,431.07**	**6,621.56**	**5,630.21**	**22,801.16**
Expenses:				
Cost of materials consumed	1,485.63	1,652.03	1,622.05	7,135.92
Changes in inventories of finished goods, work-in-progress and stock in trade	(23.64)	502.54	686.72	986.91
Employee benefit expenses	788.36	724.77	720.32	2,827.05
Finance cost	8.87	19.00	16.10	68.94
Depreciation and amortisation expense	299.87	395.91	264.46	1,340.70
Other expenses	426.16	557.94	458.08	1,955.33
Total expenses	**2,985.25**	**3,852.19**	**3,767.73**	**14,314.85**
Profit before exceptional items and tax	**1,445.81**	**2,769.36**	**1,862.48**	**8,486.31**
Exceptional items	-	(9.80)	-	243.91
Profit before tax	**1,445.81**	**2,779.16**	**1,862.48**	**8,242.40**
Tax expense				
Current tax	347.05	897.06	500.69	2,413.05
Deferred tax	(100.65)	(15.47)	3.89	(88.58)
Total tax expenses	**246.40**	**881.58**	**504.58**	**2,324.47**
Profit for the Period/Year	**1,199.41**	**1,897.58**	**1,357.91**	**5,917.92**
Other comprehensive income				
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	9.46	(10.30)	20.40	(20.83)
Income tax on above	(2.37)	2.64	(5.13)	5.18
Other comprehensive income/(loss) to be reclassified to profit or loss in subsequent period	2.83	-	-	-
Income tax on above	(0.71)	-	-	-
Other comprehensive income/(loss) for the period/year	**9.20**	**(7.66)**	**15.27**	**(15.65)**
Total comprehensive income for the period/year	**1,208.61**	**1,889.92**	**1,373.18**	**5,902.28**
Paid-up equity share capital (face value of Rs.2 each)	**1,126.77**	**1,123.43**	**1,123.22**	**1,123.43**
Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'				**29,301.73**
Earnings per share	*Not annualised*	*Not annualised*	*Not annualised*	*Annualised*
Basic	2.13	3.38	2.43	10.55
Diluted	2.11	3.34	2.42	10.43

See accompaning notes to financial results

Anthem Biosciences Limited Bangalore

K.P. RAO & CO. BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

Notes to consolidated financial results

1 These unaudited consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations") .

2 The above statement of unaudited consolidated financial results ("the Statements") of the Company for the quarter ended 30th June 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 21st July 2026. The Statutory Auditor have expressed an unmodified opinion.

3 During the quarter, the company has allotted 1,670,909 nos of fully paid up equity shares of Rs.2 each under "ESOP Scheme 2024" on approval accorded by the Board of Directors of the company at their meetings held on May 19, 2026 & June 16, 2026.

4 The consolidated financial statements include the financial results of Anthem Biosciences Limited (Parent Company) and of the following subsidiaries:
Neoanthem Lifesciences Private limited (wholly owned subsidiary)

5 Prior period/year figures have been reclassified wherever required to confirm to the classification of the current period/year.

For and on behalf of the board of directors of
Anthem Biosciences Limited
CIN:L24233KA2006PLC039703

Ajay Bhardwaj
Managing Director
DIN: 00333704

Place: Bangalore
Date: July 21, 2026

Anthem Biosciences Limited

CONSOLIDATED SEGMENT INFORMATION

Sl.No	Particulars	Quarter Ended			Year Ended
		30/06/2026	31/03/2026	30/06/2025	31/03/2026
		Unaudited	Unaudited	Unaudited	Audited
I	**Segment wise revenue and results:**				
	Segment revenue:				
	a)CRDMO	3,408.02	5,128.36	4,527.11	17,727.68
	b)Speciality Ingredients	774.16	981.07	874.98	3,515.65
	Total	**4,182.18**	**6,109.43**	**5,402.09**	**21,243.33**
II	**Segmental Results:**				
	Gross profits from each segment				
	a)CRDMO	2,322.57	3,438.30	2,648.72	11,329.85
	b)Speciality Ingredients	397.62	516.58	444.60	1,790.65
	Total	**2,720.20**	**3,954.88**	**3,093.32**	**13,120.50**
	Less: Selling and un-allocable expenditure net of other income	1,274.38	1,175.72	1,230.84	4,878.10
	Total profit before tax:	**1,445.81**	**2,779.16**	**1,862.48**	**8,242.40**

Note: The assets and liabilities of the Company are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment.Hence, assets and liabilities have not been identified to any of the reportable segments.

K.P. RAO & CO. BENGALURU FRN:003135S CHARTERED ACCOUNTANTS

Anthem Biosciences Limited Bangalore